FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

FDA Regenerative Medicine Therapies Information

FDA issues two documents with information on its work involving regenerative medicine therapies.

Human Drugs

SCOTUS Changes Impossibility Preemption Landscape

Attorney Ethan Townsend says a recent Supreme Court decision will change the landscape and introduce new uncertainty into companies use of the impossi...

Human Drugs

Amarin Priority Review for Vascepa sNDA

FDA accepts for priority review an Amarin supplemental NDA for Vascepa (icosapent ethyl) capsules, indicated to reduce residual cardiovascular risk in...

Human Drugs

SCOTUS Backs GSK in Paxil Warning Case

The Supreme Court refuses to set aside an appeals court ruling siding with GlaxoSmithKline in a Paxil failure-to-warn case.

Human Drugs

Breakthrough Status for Aliqopa Expanded Use

FDA grants Bayer a Breakthrough Therapy Designation for Aliqopa (copanlisib) for treating adult patients with relapsed marginal zone lymphoma who have...

Medical Devices

Medtronic SelectSite C304-HIS Deflectable Catheter Cleared

FDA clears a Medtronic 510(k) for the SelectSite C304-HIS deflectable catheter system for use in procedures involving His-bundle pacing.

Human Drugs

Celgenes Revlimid Approved for Expanded Combo Use

FDA approves a Celgene supplemental NDA for Revlimid (lenalidomide) in combination with rituximab for treating adult patients with previously treated ...

FDA General

Latest FDA Warning Letter

FDA releases its latest batch of Warning Letters that includes one medical product company AMMD Labs.

Human Drugs

Few Cancer Accelerated Approval Drugs Confirm Value: Study

Researchers say confirmatory trials for only 20% of cancer drug indications approved via accelerated approval demonstrated improvement in overall pati...

Human Drugs

Drug Benefit-Risk Assessment Framework Explained

Two FDAers set a context and background for agency efforts to develop a drug benefit-risk assessment framework and process as part of a public meeting...